Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6070)	4/3/2002 9:13:33 PM
From: sammaster	Read Replies (1) \| Respond to of 52153

i agree that natrecor will become a blockbuster drug... i have not really delved to much into scios besides its drug natrecor.... does it have a good product pipeline? in reference to genz... do you view the recent pullback a a buying opportunity with the announced inventory adjustment in renagel? seems like the company is valued at around 9 times sales already.... i do think that renagel has a huge market as it expands internationally and also gains further usage over cheaper substitutes